$TYRA
Tyra Biosciences, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024033461 Filed on March 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.119M $4.957M $17.43M
YoY Change 30.39% 7.34% 9.47%
% of Gross Profit
Research & Development $17.20M $20.68M $62.52M
YoY Change 65.29% 98.82% 45.36%
% of Gross Profit
Depreciation & Amortization $122.0K $102.0K $353.0K
YoY Change 46.99% 24.39% 19.26%
% of Gross Profit
Operating Expenses $22.32M $25.63M $79.95M
YoY Change 55.73% 70.69% 35.67%
Operating Profit -$22.32M -$79.95M
YoY Change 55.73% 35.67%
Interest Expense $4.130M $2.815M $10.85M
YoY Change 68.23% 30.57% 197.1%
% of Operating Profit
Other Income/Expense, Net $4.130M -$11.00K -$39.00K
YoY Change 68.3% -66.67% -101.08%
Pretax Income -$18.19M -$22.83M -$69.13M
YoY Change 53.13% 77.05% 24.96%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$18.19M -$22.83M -$69.13M
YoY Change 53.13% 77.05% 24.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.35 -$1.62
Diluted Earnings Per Share -$0.35 -$0.53 -$1.62
COMMON SHARES
Basic Shares Outstanding 52.52M 43.06M 42.70M
Diluted Shares Outstanding 52.23M 42.70M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $382.5M $203.5M $203.5M
YoY Change 58.24% -19.01% -19.01%
Cash & Equivalents $254.4M $58.01M $58.01M
Short-Term Investments $128.1M $145.5M $145.5M
Other Short-Term Assets $8.316M $8.202M $8.202M
YoY Change 66.05% 35.01% 35.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $390.8M $211.7M $211.7M
YoY Change 58.4% -17.73% -17.73%
LONG-TERM ASSETS
Property, Plant & Equipment $1.593M $8.154M $8.154M
YoY Change 52.0% 657.1% 130.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.958M $6.032M $6.032M
YoY Change 27.98% 38.67% 12.75%
Total Long-Term Assets $13.96M $14.19M $14.19M
YoY Change 67.3% 59.52% 59.52%
TOTAL ASSETS
Total Short-Term Assets $390.8M $211.7M $211.7M
Total Long-Term Assets $13.96M $14.19M $14.19M
Total Assets $404.7M $225.9M $225.9M
YoY Change 58.69% -15.15% -15.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.879M $4.662M $4.662M
YoY Change 124.92% 307.16% 307.16%
Accrued Expenses $5.837M $10.67M $10.67M
YoY Change 143.01% 134.22% 134.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.716M $15.33M $15.33M
YoY Change 136.72% 168.95% 168.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $29.00K $6.262M $6.262M
YoY Change -79.14% 3605.33% 136.21%
Total Long-Term Liabilities $29.00K $6.262M $6.262M
YoY Change -79.14% 3605.33% 136.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.716M $15.33M $15.33M
Total Long-Term Liabilities $29.00K $6.262M $6.262M
Total Liabilities $14.86M $21.60M $21.60M
YoY Change 137.22% 158.56% 158.56%
SHAREHOLDERS EQUITY
Retained Earnings -$183.0M -$164.8M
YoY Change 70.13% 72.2%
Common Stock $572.9M $368.7M
YoY Change 60.76% 4.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $389.9M $204.3M $204.3M
YoY Change
Total Liabilities & Shareholders Equity $404.7M $225.9M $225.9M
YoY Change 58.69% -15.15% -15.15%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$18.19M -$22.83M -$69.13M
YoY Change 53.13% 77.05% 24.96%
Depreciation, Depletion And Amortization $122.0K $102.0K $353.0K
YoY Change 46.99% 24.39% 19.26%
Cash From Operating Activities -$22.03M -$13.53M -$50.14M
YoY Change 123.7% 12.95% -0.29%
INVESTING ACTIVITIES
Capital Expenditures $136.0K $603.0K $770.0K
YoY Change 231.71% 2771.43% 37.75%
Acquisitions
YoY Change
Other Investing Activities $18.21M -$143.8M -$143.8M
YoY Change
Cash From Investing Activities $18.07M -$144.4M -$144.6M
YoY Change -44180.49% 687700.0% 25768.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.537M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.3M 324.0K 1.537M
YoY Change 53175.27% 10700.0% 143.2%
NET CHANGE
Cash From Operating Activities -22.03M -13.53M -50.14M
Cash From Investing Activities 18.07M -144.4M -144.6M
Cash From Financing Activities 200.3M 324.0K 1.537M
Net Change In Cash 196.4M -157.6M -193.2M
YoY Change -2164.34% 1213.94% 284.78%
FREE CASH FLOW
Cash From Operating Activities -$22.03M -$13.53M -$50.14M
Capital Expenditures $136.0K $603.0K $770.0K
Free Cash Flow -$22.16M -$14.14M -$50.91M
YoY Change 124.15% 17.78% 0.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001863127
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40800
CY2023 dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2023 dei City Area Code
CityAreaCode
619
CY2023 dei Local Phone Number
LocalPhoneNumber
728-4760
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
TYRA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
267400000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52521050
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58006000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251213000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
145463000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8202000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6075000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
211671000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
257288000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1628000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2023Q4 tyra Right Of Use Asset
RightOfUseAsset
6526000
CY2022Q4 tyra Right Of Use Asset
RightOfUseAsset
2466000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5032000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4350000
CY2023Q4 us-gaap Assets
Assets
225857000
CY2022Q4 us-gaap Assets
Assets
266181000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4662000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1145000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
280000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
140000
CY2023Q4 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
0
CY2022Q4 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
59000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10391000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15333000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5701000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6216000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2482000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
169000
CY2023Q4 us-gaap Liabilities
Liabilities
21595000
CY2022Q4 us-gaap Liabilities
Liabilities
8352000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43099055
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42634459
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43024634
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42353550
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
368707000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
353521000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
381000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164830000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95696000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
204262000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
225857000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
266181000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62518000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43008000
CY2023 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
0
CY2022 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
765000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17427000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15919000
CY2023 us-gaap Operating Expenses
OperatingExpenses
79945000
CY2022 us-gaap Operating Expenses
OperatingExpenses
58927000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-79945000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-58927000
CY2023 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
10850000
CY2022 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
3652000
CY2023 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
39000
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
50000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10811000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3602000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-69134000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
381000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68753000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55325000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42704876
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42704876
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41883904
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41883904
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
632000
CY2022 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
197000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10588000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
1537000
CY2023 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
124000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13525000
CY2023 tyra Available For Sale Debt Securities Net Unrealized Gain
AvailableForSaleDebtSecuritiesNetUnrealizedGain
381000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-69134000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
204262000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-69134000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
353000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
296000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
13525000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
10588000
CY2023 tyra Accretion On Marketable Securities Net
AccretionOnMarketableSecuritiesNet
-1247000
CY2022 tyra Accretion On Marketable Securities Net
AccretionOnMarketableSecuritiesNet
0
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2023 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2823000
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
8238000
CY2023Q4 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
0
CY2022Q4 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
12000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9369000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2357000
CY2023 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-186000
CY2022 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
34000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50139000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50285000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
143835000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
770000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
559000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-144605000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-559000
CY2023 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
1537000
CY2022 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
632000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1537000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
632000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-193207000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50212000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59006000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58006000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251213000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59006000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4405000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1572000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
125000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2023 tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
124000
CY2022 tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
197000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164800000
CY2023Q4 tyra Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
203500000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accounting estimates and management judgments reflected in the financial statements include: normal recurring accruals, including the accrual of research and development expenses and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.</span></p>
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1000000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1000000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
132000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2023Q4 tyra Accrued Other General And Administrative Fee
AccruedOtherGeneralAndAdministrativeFee
294000
CY2022Q4 tyra Accrued Other General And Administrative Fee
AccruedOtherGeneralAndAdministrativeFee
440000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10391000
CY2023 us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero.
CY2023 tyra Dividend Yield
DividendYield
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145082000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
384000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
145463000
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
9939000
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2023 us-gaap Fair Value Option Credit Risk Gains Losses On Assets
FairValueOptionCreditRiskGainsLossesOnAssets
9939000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
9900000
CY2023Q4 tyra Accrued Interest Available For Sale Securities
AccruedInterestAvailableForSaleSecurities
700000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2435000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1538000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
807000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
461000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1628000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2023 us-gaap Depreciation
Depreciation
400000
CY2022 us-gaap Depreciation
Depreciation
300000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5117000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2854000
CY2023Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
4848000
CY2022Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1028000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2023Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
8276442
CY2022Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
5890869
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13083154
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10989684
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5890869
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.91
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13492000
CY2023 tyra Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod
3196639
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.26
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
408209
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.8
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
402857
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.13
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8276442
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.07
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40420000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3180912
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.3
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22393000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8276442
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.07
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
40420000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13525000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10588000
CY2022 tyra Forfeitures Resulted In The Reversal Of Compensation Expense
ForfeituresResultedInTheReversalOfCompensationExpense
200000
CY2023 tyra Forfeitures Resulted In The Reversal Of Compensation Expense
ForfeituresResultedInTheReversalOfCompensationExpense
200000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
40600000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2022 tyra Incremental Stock Based Compensation Recorded Due To Terminations
IncrementalStockBasedCompensationRecordedDueToTerminations
2000000
CY2022 tyra Accelerate Expense Or Compensation Cost Expense Recognized Due To Termination
AccelerateExpenseOrCompensationCostExpenseRecognizedDueToTermination
1200000
CY2022 tyra Stock Compensation Expense Related To Modification Of Options
StockCompensationExpenseRelatedToModificationOfOptions
800000
CY2023Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
74421
CY2022Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
277081
CY2023Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
100000
CY2022Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
200000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-69134000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2023 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42882832
CY2022 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42627825
CY2023 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-2393
CY2022 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-269174
CY2023 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
175563
CY2022 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
474746
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42704876
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42704876
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41883904
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41883904
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8377898
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6191259
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14518000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11618000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-67000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-58000
CY2023 tyra Incometaxreconciliation Officers Compensation
IncometaxreconciliationOfficersCompensation
389000
CY2022 tyra Incometaxreconciliation Officers Compensation
IncometaxreconciliationOfficersCompensation
598000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
1000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-120000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-375000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
827000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3345000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2093000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
17915000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12466000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14126000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11596000
CY2023Q4 tyra Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
16906000
CY2022Q4 tyra Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
7097000
CY2023Q4 tyra Deferred Tax Assets Tax Credits
DeferredTaxAssetsTaxCredits
6412000
CY2022Q4 tyra Deferred Tax Assets Tax Credits
DeferredTaxAssetsTaxCredits
2958000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2871000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1016000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2248000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1090000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42563000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23757000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40920000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23085000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1643000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
672000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
266000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
151000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1377000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
521000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1643000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
672000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40900000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17800000
CY2023 tyra Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage
NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage
0.80
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1574000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1142000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
605000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
366000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
827000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
66000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3006000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1574000
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
800000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
708000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
322000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
61000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
81000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
79000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
56000
CY2023 us-gaap Lease Cost
LeaseCost
848000
CY2022 us-gaap Lease Cost
LeaseCost
459000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
772000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
873000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
899000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
926000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
954000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5027000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9451000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2955000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6496000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
280000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6216000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0807
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
42

Files In Submission

Name View Source Status
0000950170-24-033461-index-headers.html Edgar Link pending
0000950170-24-033461-index.html Edgar Link pending
0000950170-24-033461.txt Edgar Link pending
0000950170-24-033461-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img23526391_0.jpg Edgar Link pending
img23526391_1.jpg Edgar Link pending
img23526391_10.jpg Edgar Link pending
img23526391_11.jpg Edgar Link pending
img23526391_12.jpg Edgar Link pending
img23526391_13.jpg Edgar Link pending
img23526391_14.jpg Edgar Link pending
img23526391_15.jpg Edgar Link pending
img23526391_16.jpg Edgar Link pending
img23526391_17.jpg Edgar Link pending
img23526391_18.jpg Edgar Link pending
img23526391_19.jpg Edgar Link pending
img23526391_2.jpg Edgar Link pending
img23526391_20.jpg Edgar Link pending
img23526391_21.jpg Edgar Link pending
img23526391_22.jpg Edgar Link pending
img23526391_23.jpg Edgar Link pending
img23526391_24.jpg Edgar Link pending
img23526391_25.jpg Edgar Link pending
img23526391_26.jpg Edgar Link pending
img23526391_27.jpg Edgar Link pending
img23526391_28.jpg Edgar Link pending
img23526391_29.jpg Edgar Link pending
img23526391_3.jpg Edgar Link pending
img23526391_30.jpg Edgar Link pending
img23526391_31.jpg Edgar Link pending
img23526391_4.jpg Edgar Link pending
img23526391_5.jpg Edgar Link pending
img23526391_6.jpg Edgar Link pending
img23526391_7.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img23526391_8.jpg Edgar Link pending
img23526391_9.jpg Edgar Link pending
img51495336_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20231231.htm Edgar Link pending
tyra-20231231.xsd Edgar Link pending
tyra-ex10_23.htm Edgar Link pending
tyra-ex23_1.htm Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending
tyra-ex97_1.htm Edgar Link pending
tyra-20231231_htm.xml Edgar Link completed